Understanding Amyotrophic Lateral Sclerosis: Pathophysiology, Diagnosis, and Therapeutic Advances

被引:1
|
作者
Rizea, Radu Eugen [1 ,2 ]
Corlatescu, Antonio-Daniel [1 ]
Costin, Horia Petre [1 ]
Dumitru, Adrian [1 ,3 ,4 ]
Ciurea, Alexandru Vlad [1 ,5 ]
机构
[1] Univ Med & Pharm, Dept Neurosurg, Bucharest 020021, Romania
[2] Bagdasar Arseni Emergency Clin Hosp, Dept Neurosurg, Bucharest 041915, Romania
[3] Univ Med & Pharm, Dept Morphopathol, Bucharest 020021, Romania
[4] Emergency Univ Hosp Bucharest, Bucharest 050098, Romania
[5] Sanador Clin Hosp, Bucharest 010991, Romania
关键词
amyotrophic lateral sclerosis (ALS); therapeutic approaches; gene therapy; stem cell therapy; biomarkers; neurodegeneration; AWAJI CRITERIA; ALS; FUS; TDP-43; MUTATIONS; GENE; PREVALENCE; MICROGLIA; PROTEINS; STRESS;
D O I
10.3390/ijms25189966
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review offers an in-depth examination of amyotrophic lateral sclerosis (ALS), addressing its epidemiology, pathophysiology, clinical presentation, diagnostic techniques, and current as well as emerging treatments. The purpose is to condense key findings and illustrate the complexity of ALS, which is shaped by both genetic and environmental influences. We reviewed the literature to discuss recent advancements in understanding molecular mechanisms such as protein misfolding, mitochondrial dysfunction, oxidative stress, and axonal transport defects, which are critical for identifying potential therapeutic targets. Significant progress has been made in refining diagnostic criteria and identifying biomarkers, leading to earlier and more precise diagnoses. Although current drug treatments provide some benefits, there is a clear need for more effective therapies. Emerging treatments, such as gene therapy and stem cell therapy, show potential in modifying disease progression and improving the quality of life for ALS patients. The review emphasizes the importance of continued research to address challenges such as disease variability and the limited effectiveness of existing treatments. Future research should concentrate on further exploring the molecular foundations of ALS and developing new therapeutic approaches. The implications for clinical practice include ensuring the accessibility of new treatments and that healthcare systems are equipped to support ongoing research and patient care.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Pathophysiology of ion channels in amyotrophic lateral sclerosis
    Stringer, Robin N.
    Weiss, Norbert
    MOLECULAR BRAIN, 2023, 16 (01)
  • [22] PATHOPHYSIOLOGY OF FATIGUE IN AMYOTROPHIC-LATERAL-SCLEROSIS
    SHARMA, KR
    KENTBRAUN, J
    MAJUMDAR, S
    MYNHIER, M
    WEINER, M
    MILLER, RG
    NEUROLOGY, 1993, 43 (04) : A256 - A257
  • [23] Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
    Vucic, Steve
    Kiernan, Matthew C.
    CURRENT MOLECULAR MEDICINE, 2009, 9 (03) : 255 - 272
  • [24] Pathophysiology of ion channels in amyotrophic lateral sclerosis
    Robin N. Stringer
    Norbert Weiss
    Molecular Brain, 16
  • [25] Recent advances in amyotrophic lateral sclerosis
    Riva, Nilo
    Agosta, Federica
    Lunetta, Christian
    Filippi, Massimo
    Quattrini, Angelo
    JOURNAL OF NEUROLOGY, 2016, 263 (06) : 1241 - 1254
  • [26] Amyotrophic Lateral Sclerosis: Advances and Prospects
    Boentert, Matthias
    Hermann, Andreas
    Grosskreutz, Julian
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [27] Recent advances in amyotrophic lateral sclerosis
    Nilo Riva
    Federica Agosta
    Christian Lunetta
    Massimo Filippi
    Angelo Quattrini
    Journal of Neurology, 2016, 263 : 1241 - 1254
  • [28] Understanding the causes of amyotrophic lateral sclerosis
    Orrell, Richard W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (08): : 822 - 823
  • [29] Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials
    Gordon, Paul H.
    AGING AND DISEASE, 2013, 4 (05): : 295 - 310
  • [30] Therapeutic opportunities in amyotrophic lateral sclerosis
    Eisen, A
    NEUROLOGIST, 1996, 2 (02) : 85 - 95